The Acute Impact of Smoking One Cigarette on Cardiac Hemodynamic Parameters

Khalid Abou Farha, Ramy Abou Farha, Marc Bolt

Abstract

Background: The acute impact of tobacco smoking on the cardiac hemodynamic parameters and its pathological implication in the process of arterial atherosclerosis need further exploration. This investigation was purposed to assess the acute impact of tobacco smoke on blood pressure and cardiac hemodynamic parameters.

Methods: Using an Ultrasonic Cardiac Output Monitor, and DINAMAP Pro 400 Series V2 blood pressure monitor, several cardiac hemodynamic parameters and the blood pressure were assessed in 14 smokers, 11 females and 3 males, at 2 time points, before and after smoking of one cigarette. Data, in terms of ratio of the means and 95% confidence interval were analyzed using ANOVA.

Results: Single-subject design in which the subject has served as his/her own control has been used. Tobacco smoking led to statistically significant acute increase in the means of all hemodynamic parameters, except for heart rate in female subjects, as compared to the means obtained before smoking.

Conclusions: Cigarette smoking induces acute non-physiologic alteration in cardiac outflow forces, exposing the aortic valve and arch to mechanical injury that might be implicated in initiating and promoting the process of aortic arch atherosclerosis and associated pathological lesions.

Keywords: Smoking; Cigarette; Cardiac hemodynamic parameters

Introduction

The use of tobacco leaf for treatment of various illnesses and sometimes for its pleasurable effect was introduced by the Native Americans to Columbus as early as the 15th of October 1492. However the use of tobacco as cigarette is a 20th century phenomenon [1].

Tobacco smoking is the leading preventable cause of death (40%) [2]. Cardiovascular diseases (CVD) have been shown to be the leading cause of death from smoking. In the year 2003 there were 4.83 million premature deaths in the world attributable to smoking. CVDs caused 1.69 million of these [3]. It is estimated that 26% of people aged 15 years and older in the EU, or about 100 million people, are current daily smokers and about 50 million of these will die prematurely from smoking unless they quit [4]. Moreover, it has been estimated that by 2030 tobacco is going to kill 8 million people a year [5].

The average cigarette contains 6 - 11 mg nicotine and delivers about 1 - 3 mg nicotine systemically to the smoker [6]. The inhaled cigarette smoke is rapidly absorbed from small airways and alveoli reaching a blood maximum concentration after 5 - 8 minutes and declines over the next 20 minutes due to tissue distribution [7, 8]. The intake of nicotine during smoking depends on the puff volume, the extent of dilution with room air, rate of puffing and extent of swallowing nicotine laden saliva [7]. Nicotine is eliminated mainly by hepatic metabolism (80% - 90%) and also by the kidney with a half-life elimination time of 2 hour [6, 7].

The effect of smoking on cardiovascular system is multifactorial. Cigarette smoking induces and promotes a progressive interlacing complex process that might end up with vascular occlusion, myocardial infarction and stroke. Tobacco smoking has been identified as a strong and independent cause of vascular atherosclerosis and is reported as a major cause of occlusive arterial diseases (including coronary arteries), aortic valve stenosis and thoracic aortic dilatation and aneurysm, specifically in the aortic arch [9-11]. Cigarette smoking-induced atherosclerosis is partly attributed to the vascular endothelial damage caused by the free radicals and reactive oxygen species (ROS) in the cigarette smok-
ing and by decreasing the nitric oxide (NO) bioactivity in vascular endothelium as well as platelet derived NO release [2]. NO is a regulator of the mitochondrial ROS detoxification system. Reduced levels of NO lead to ROS high levels resulting in lipid peroxidation and damage to cell membranes, protein and DNA and ultimately result in vascular endothelial cell dysfunction and death [12]. Although the entire vascular endothelium is exposed to the above-mentioned tobacco-induced humoral responses, atherosclerotic lesions develop preferentially at certain sites including the inner curvatures of the arteries, like aortic arch. This suggest the presence of other local factors that promote disease susceptibility like disturbed cardiac hemodynamic forces that might lead to non-physiologic mechanical stress effects [10, 13].

To the best of our knowledge, the acute change in the cardiac hemodynamic profile induced by tobacco smoking and its impact on the cardiovascular integrity are scarcely addressed in the literature. Given that, we decided to conduct this pilot cross-sectional investigation to explore the acute effect of smoking one cigarette on a number of cardiac hemodynamic parameters and blood pressure.

**Methods**

**Subjects**

We performed a pilot cross-sectional study to investigate the acute effect of cigarette smoking on a number of cardiac hemodynamic parameters and blood pressure. Fourteen young healthy subjects, 11 females and 3 males, aged 24 - 51 years served as study population. All subjects were regular smokers (10 - 20 cigarettes per day for 5 - 25 years). All subjects included in this pilot study are employees of the clinical pharmacology institute of PRA-international, Groningen, the Netherlands. A written consent form to publish the study data has been obtained from all participated subjects. All female participants were using hormonal contraception.

### Table 1. Statistical Analysis Parameters Measured Before and After Smoking (All N = 14)

| Parameter | LS means | Ratio (after/before) | Geometric mean | Confidence interval 95% | Pr > |t| * |
|-----------|----------|----------------------|----------------|-------------------------|----------|
|           | Before   | After   | Lower | Upper |               |          |
| VPK       | 1.04     | 1.23    | 1.18  | 1.08  | 1.30           | 0.0019   |
| PMN       | 2.05     | 2.83    | 1.58  | 1.20  | 1.59           | 0.0003   |
| HR        | 69.7     | 76.0    | 1.09  | 1.04  | 1.14           | 0.0013   |
| MD        | 14.5     | 19.6    | 1.35  | 1.23  | 1.48           | < 0.0001 |
| ET%       | 34.9     | 40.5    | 1.16  | 1.12  | 1.20           | < 0.0001 |
| SV        | 69.9     | 86.0    | 1.23  | 1.15  | 1.32           | < 0.0001 |
| SVI       | 35.3     | 43.2    | 1.22  | 1.14  | 1.32           | < 0.0001 |
| COP       | 4.89     | 6.51    | 1.33  | 1.22  | 1.46           | < 0.0001 |
| CI        | 2.45     | 3.30    | 1.35  | 1.22  | 1.49           | < 0.0001 |
| SBP       | 130      | 135     | 1.04  | 0.98  | 1.10           | 0.1987*  |
| DBP       | 81.5     | 83.6    | 1.03  | 0.98  | 1.07           | 0.1968*  |
| PP        | 48.1     | 51.1    | 1.06  | 0.96  | 1.18           | 0.2327*  |
| MBP       | 97.8     | 101     | 1.03  | 0.98  | 1.08           | 0.1815*  |
| HR x PP   | 3351     | 3882    | 1.16  | 1.01  | 1.32           | 0.0323   |

The parameters were analyzed with ANOVA, treatment (pre- or post-smoking) and treatment* gender as fixed factors and subject as a random factor.

The values were (natural) LOG transformed before (and back transformed after) statistical analysis.

*indicates if the P-value is above 0.05 (no alpha level was pre-defined).
No other medications including over the counter medications were used by any of the participated subjects. None of the subjects had a history of any relevant medical disease. The cardiac hemodynamic parameters and brachial blood pressure were assessed at 2 time points, after 3-5 minutes rest, before smoking (at least 2 hours refrain from smoking, served as a baseline value) and up to 15 minutes after smoking.

Echocardiographic assessments

In this investigation we used the Ultrasonic Cardiac Output Monitor (USCOM Pty Ltd, Coffs Harbour, NSW, Australia). USCOM is a well validated non-invasive device that determines cardiac output by a continuous-wave (C-W) Doppler Ultrasound [13]. The USCOM machine displays many real-time data about cardiac hemodynamic through evaluating the aortic or pulmonary blood flow as it leaves the heart. Validated internal algorithms calculate the diameter of the aortic and pulmonary valve based upon the patient’s height and weight. Using a 2.2 MHz USCOM transducer we assessed the following systolic flow profiles: heart rate (HR); cardiac output (COP); cardiac index (CI); stroke volume (SV); stroke volume index (SVI); aortic peak velocity (VpK); minute distance (MD); ejection time percentage (ET%); and mean pressure gradient (Pmn). In this regard, the suprasternal notch acoustic window has been selected to scan, for at least one minute, the flow profile of several cardiac cycles (one cardiac cycle is ± 0.8 seconds) obtained from each subject in the supine position. The average of values obtained for each parameter was subsequently considered in the evaluation. To avoid the possibility of inter-observer variation and tracing different blood flow strengths and subsequently signaling different hemodynamic profiles, one investigator made the assessment by placing the transducer on the same point of optimal acoustic signal displayed as pointy peak on the USCOM screen. As for assessment of blood pressure, the well validated and widely used DINAMAP Pro 400 Series

| Parameter | LS means | Ratio (after/before) | Confidence interval 95% | Pr > |t| *
|-----------|----------|----------------------|-------------------------|------|-----|
|           | Before   | After                | Geometric mean Lower    | Upper|      |
| VPK       | 1.21     | 1.39                 | 1.16                    | 1.06 | 1.26 | 0.0032 |
| PMN       | 2.61     | 3.39                 | 1.30                    | 1.14 | 1.48 | 0.0010 |
| HR        | 75.8     | 78.4                 | 1.03                    | 0.99 | 1.08 | 0.1078* |
| MD        | 19.9     | 24.6                 | 1.24                    | 1.14 | 1.35 | 0.0002 |
| ET%       | 43.0     | 46.8                 | 1.09                    | 1.05 | 1.12 | 0.0001 |
| SV        | 85.7     | 102                  | 1.19                    | 1.12 | 1.27 | <0.0001 |
| SVI       | 44.9     | 53.5                 | 1.19                    | 1.11 | 1.27 | <0.0001 |
| COP       | 6.50     | 7.93                 | 1.22                    | 1.12 | 1.33 | 0.0002 |
| CI        | 3.40     | 4.18                 | 1.23                    | 1.12 | 1.35 | 0.0004 |
| SBP       | 129      | 132                  | 1.02                    | 0.97 | 1.08 | 0.4344* |
| DBP       | 75.6     | 78.3                 | 1.03                    | 1.00 | 1.08 | 0.0760* |
| PP        | 53.1     | 53.1                 | 1.00                    | 0.91 | 1.10 | 0.9937* |
| MBP       | 93.5     | 96.2                 | 1.03                    | 0.98 | 1.07 | 0.1924* |
| HR x PP   | 4029     | 4167                 | 1.03                    | 0.92 | 1.17 | 0.5579* |

The parameters were analyzed with ANOVA, treatment (pre- or post-smoking) and treatment* gender as fixed factors and subject as a random factor.

The values were (natural) LOG transformed before (and back transformed after) statistical analysis.

*indicates if the P-value is above 0.05 (no alpha level was pre-defined).
V2, GE medical system was used. Brachial blood pressure, Systolic (SBP) and Diastolic (DBP) were measured. Derived variables were calculated as follows: Mean arterial blood pressure (MAP) = 1/3 SBP + 2/3 DBP and Pulse Pressure (PP) = SBP - DBP.

**Statistical analysis**

Single-subject design in which the subject served as his/her own control has been used. The data were analyzed with ANOVA. To analyze the hemodynamic parameters, a mixed model was applied using treatment (pre- or post-smoking) and gender by treatment as fixed effects and subject as a random factor. The individual values were (natural) LOG transformed before (and back transformed after) statistical analysis. *indicates if the P-value is above 0.05 (no alpha level was pre-defined).

**Results**

In this investigation a statistically significant difference at the level of ≤ 0.02 between all cardiac hemodynamic values (except for HR in female subjects) obtained before and after smoking has been observed. In spite of the small sample size (14 subjects) used in this pilot cross-sectional study, there was an obvious increase in the means of the assessed hemodynamic parameters obtained after smoking. At the individual subject level, 4 female subjects demonstrated no changes in some hemodynamic parameters obtained after smoking as compared to base line values; Vpk, Pmn, MD, ET% and COP in one subject; Vpk and HR in one subject. Table 3 shows the analysis parameters measured before and after smoking (Male N = 3).

### Table 3. Analysis Parameters Measured Before and After Smoking (Male N = 3)

| Parameter | LS means Before | Ratio (after/before) | Geometric mean | Confidence interval 95% Lower | Confidence interval 95% Upper | Pr > |t| * |
|-----------|-----------------|----------------------|----------------|-------------------------------|-------------------------------|--------|------|
| VPK       | 0.901           | 1.09                 | 1.21           | 1.03                          | 1.43                          | 0.0256 |
| PMN       | 1.61            | 2.37                 | 1.47           | 1.14                          | 1.88                          | 0.0061 |
| HR        | 64.0            | 73.6                 | 1.15           | 1.06                          | 1.25                          | 0.0025 |
| MD        | 10.5            | 15.5                 | 1.48           | 1.25                          | 1.74                          | 0.0002 |
| ET%       | 28.4            | 35.0                 | 1.24           | 1.16                          | 1.32                          | < 0.0001 |
| SV        | 57.1            | 72.7                 | 1.27           | 1.13                          | 1.44                          | 0.0010 |
| SVI       | 27.7            | 34.9                 | 1.26           | 1.11                          | 1.43                          | 0.0021 |
| COP       | 3.67            | 5.34                 | 1.45           | 1.24                          | 1.71                          | 0.0003 |
| CI        | 1.76            | 2.62                 | 1.49           | 1.24                          | 1.77                          | 0.0004 |
| SBP       | 131             | 139                  | 1.06           | 0.95                          | 1.17                          | 0.2877 |
| DBP       | 87.7            | 89.3                 | 1.02           | 0.95                          | 1.10                          | 0.6074 |
| PP        | 43.6            | 49.1                 | 1.13           | 0.94                          | 1.36                          | 0.1829 |
| MBP       | 102             | 106                  | 1.03           | 0.95                          | 1.13                          | 0.3968 |
| HR x PP   | 2788            | 3616                 | 1.30           | 1.03                          | 1.64                          | 0.0325 |

The parameters were analyzed with ANOVA, treatment (pre- or post-smoking) and treatment* gender as fixed factors and subject as a random factor. The values were (natural) LOG transformed before (and back transformed after) statistical analysis. *indicates if the P-value is above 0.05 (no alpha level was pre-defined).
Figure 1. Cardiac output (COP), individual values.

Figure 2. Aortic peak velocity (VpK), individual values.

Figure 3. Aortic valve mean pressure gradient (Pmn), individual values.

Figure 4. Stroke volume (SV), individual values.

Figure 5. Minute distance (MD), individual values.

Figure 6. Ejection time percentage (ET%), individual values.
As for the blood pressure values and derived variables, we found respectively in male and female subjects increase of 8 and 3 mmHg in SBP; increase of 1.6 and 2.7 mmHg in DBP; increase of 4 and 2.8 mmHg in MAP; and increase of 828 and 138 in the HR-PP product (pulsatile stress index) during one minute. Tables 1, 2 and 3 and Figures 1 through to 6 depict the obtained results.

**Discussion**

The concentration of nicotine in arterial blood after smoking one cigarette ranges between 20 - 100 ng/mL. In smokers, the mean nicotine boost after smoking a cigarette is 10.9 ng/mL blood. Given a 2 h half-life time for nicotine, accumulation is predicted over 8 h (4 half-life times) of regular smoking with persistence of high blood nicotine level for 8 h after cessation of smoking. This indicates that regular smokers would have increment in blood nicotine concentration as the day progress with significantly high nicotine plasma levels during sleep [7]. The cardiovascular endothelial lining of regular smokers is, therefore, continuously exposed to ascending high nicotine concentration. This pilot study showed some interesting findings. In spite of the low sample size which is expected to decrease the power of statistical analysis, smoking one cigarette was associated with significant increase in the COP, Vpk and Pmn as compared to values obtained at pre-smoking time point. The increases observed in males and females were respectively (45% and 22%), (21% and 16%) and (47% and 30%) for COP, Pmn and Vpk. The increase in these variables even across anatomically normal aortic valve can cause highly disturbed and turbulent aortic blood flow [15, 16]. Turbulent blood flow contributes to a variety of arterial pathological effects. Unlike the athero-protective normal laminar shear stress, turbulent or oscillatory blood flow induces and promotes the development of atherosclerotic plaque formation especially in atherosclerosis susceptible areas exposed to a weak net hemodynamic athero-protective shear stress, e.g., aortic arch [17]. Exposure of vascular endothelial cells (VECs) to turbulent oscillatory shear stress is associated with prolonged reactive oxygen species generation (ROS) and $\text{H}_2\text{O}_2$ production. In addition, turbulent shear stress fails to stimulate expression of endothelial nitric oxide synthase and Mn superoxide dismutase which form an important antioxidant defense system [17-19]. Protracted turbulent shear stress disturbs the balance between ROS production and ROS neutralizing enzymes which becomes tipped towards oxidative status where the produced nitric oxide is insufficient to counterbalance the increased ROS [17]. This results in increased expression of vascular cell adhesion protein molecules that bind to inflammatory cells and endothelial cell loss, apoptosis and desquamation creating leaky junctions over the endothelium that increase endothelium permeability to macromolecules including LDL [18, 20, 21]. Turbulent flow up-regulates the production of endothelin-1 that acts as a vasoconstrictor and vascular smooth muscle cell (VSMC) mitogen, a key factor in the development of vascular wall hyperplasia [19]. It also up-regulates endothelium derived bone morphogenic proteins (BMPs) suggested to induce vascular calcification [22]. The ultimate end results will be development of atherosclerosis. The observed post one cigarette smoking increase in SV, 27% and 19% in males and females respectively, reflects increase in the intraventricular pressure. Giving the fact that myocardium is only perfused during diastole, the resultant increase in intraventricular pressure together with the observed increase in the systolic ejection time (ET%), 24% in males and 9% in females, might limit the adequate coronary perfusion and myocardium oxygen supply. In addition, the observed increase in MD, 48% in males and 24% in females, Vpk and SV indicate increased myocardial contractility and thence increased myocardial oxygen demands. This together with the well-established effect of smoking in inducing arterial oxygen de-saturation [23, 24] aggravate the negative impact of smoking-induced limitation of myocardial perfusion.

The difference between all assessed blood pressure variables, except for the product of HR and PP in male subjects, did not reach statistical significance. This might be attributed to low power of the test reasoned by the small sample size. Nevertheless, the observed difference might bear some pathophysiological and clinical importance, particularly in regular smokers where the CVS is continuously exposed to cumulative plasma nicotine levels. Under normal conditions arterial vascular walls are continuously exposed to physiological levels of cyclic strains and pulsatile distension imposed by heart propulsion (stroke volume) and systolic-diastolic blood pressure phases. However, variation within normal physiologic pulsatile distension of arterial wall does not exceed 10% - 12% [25]. Non-physiologic chronic cyclic stress stimulates the expression and activity of a number of proteolytic enzymes including matrix metalloproteinases (MMP) and extracellular matrix degrading enzymes, that cleave extracellular matrix as well as non-matrix substances resulting in increased permeability to macromolecules including LDL. Cyclic strain also increases ROS generation and cleaved Caspase expression, a pro-apoptotic event. These changes result in endothelial cell dysfunction, detachment and apoptosis [20, 26]. On the other hand, mechanical stretch of the vessel wall was found to up-regulate angiotensin II receptors (AT1 receptors) and consequently sensitize VSMC to angiotensin II, a potent vasoconstrictor and extracellular matrix synthesis inducer [27]. In addition, non-physiologic increased cyclic stretch activates VSM and promotes VSMC DNA synthesis and proliferation leading to increased wall thickness and decreased vascular wall compliance [25, 28]. The pathophysiological mechanisms leading to initiation and development of arterial atherosclerosis are similar to those involved pathogenesis of aortic stenosis [11, 29].
Smoking and Cardiac Hemodynamic Parameters

Consent

Written informed consents are obtained from all subjects involved in this pilot study including that needed for publication of obtained medical data. Copies of the written informed consents are available for review by the editor-in-chief of this journal.

Competing Interests

The authors declare that they have no competing interests.

Authors’ Contributions

KA performed echocardiographic assessment and reviewed the literature, RA was involved in the collection and review of the literature and writing the manuscript and MB was involved in the statistical analysis of the obtained data. All authors read and approved the final manuscript.

References

1. Charlton A. Medicinal uses of tobacco in history. J R Soc Med 2004;97(6):292-296.
2. Smoking. In R.A.S. Hemat. Principles of Orthomolecularism. Urotex.com. P.168.
3. CVD most common cause of death from smoking (2003). The heart. Org. www.theheart.org/article/240875.do
4. Bogdanovica I, Godfrey F, McNeill A, Britton J. Smoking prevalence in the European Union: a comparison of national and transnational prevalence survey methods and results. Tob Control 2011;20(1):e4.
5. Statistics for death caused due to smoking and tobacco use (2009): smoking.ygoy.com/.../statistics-for-death-caused-due-to-smoking-and-tobacco-use
6. Brunten L, Parker K, Bkuemanthal D, Buston I. Agents acting at the neuromuscular junction and autonomic ganglia. In Brunten L, Parker K, Bkuemanthal D and Buston I (ed.): Goodman & Gilman’s manual of pharmacology and therapeutic. section II, chapter 9. McGraw-Hill companies, USA. 2008;P.135.
7. Hukkanen J, Jacob P, 3rd, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev 2005;57(1):79-115.
8. Lunell E, Molander L, Ekberg K, Wahren J. Site of nicotine absorption from a vapour inhaler--comparison with cigarette smoking. Eur J Clin Pharmacol 2000;55(10):737-741.
9. Witteman JC, Grobbee DE, Valkenburg HA, van Hemert AM, Stijnen T, Hofman A. Cigarette smoking and the development and progression of aortic atherosclerosis. A 9-year population-based follow-up study in women. Circulation 1993;88(5 Pt 1):2156-2162.
10. Agmon Y, Khandheria BK, Meissner I, Schwartz GL,
Sicks JD, Fought AJ, O’Fallon WM, et al. Is aortic dilatation an atherosclerosis-related process? Clinical, laboratory, and transesophageal echocardiographic correlates of thoracic aortic dimensions in the population with implications for thoracic aortic aneurysm formation. J Am Coll Cardiol 2003;42(6):1076-1083.

11. Rajamannan NM. Update on the pathophysiology of aortic stenosis. Eur Heart J 2008;10 (Supplement E):E4-E10.

12. Borniquel S, Valle I, Cadenas S, Lamas S, Monsalve M. Nitric oxide regulates mitochondrial oxidative stress protection via the transcriptional coactivator PGC-1alpha. FASEB J 2006;20(11):1889-1891.

13. Jongstra-Bilen J, Haidari M, Zhu SN, Chen M, Guha D, Cybulsky MI. Low-grade chronic inflammation in regions of the normal mouse arterial intima predisposed to atherosclerosis. J Exp Med 2006;203(9):2073-2083.

14. van Lelyveld-Haas LE, van Zanten AR, Borm GF, Tjan DH. Clinical validation of the non-invasive cardiac output monitor USCOM-1A in critically ill patients. Eur J Anaesthesiol 2008;25(11):917-924.

15. Stein PD, Sabbah HN. Turbulent blood flow in the ascending aorta of humans with normal and diseased aortic valves. Circ Res 1976;39(1):58-65.

16. Kalbunde RE. Turbulent blood flow. Cardiovascular Physiology Concepts. www.cvphysiology.com

17. Lehoux S. Redox signalling in vascular responses to shear and stretch. Cardiovasc Res 2006;71(2):269-279.

18. Malek AM, Alper SL, Izumo S. Hemodynamic shear stress and its role in atherosclerosis. JAMA 1999;282(21):2035-2042.

19. Qiu Y, Tarbell JM. Interaction between wall shear stress and circumferential strain affects endothelial cell biochemical production. J Vasc Res 2000;37(3):147-157.

20. Kou B, Zhang J, Singer DR. Effects of cyclic strain on endothelial cell apoptosis and tubulogenesis are dependent on ROS production via NAD(P)H subunit p2phox. Microvasc Res 2009;77(2):125-133.

21. Dabagh M, Jalali P, Tarbell JM. The transport of LDL across the deformable arterial wall: the effect of endothelial cell turnover and intimal deformation under hypertension. Am J Physiol Heart Circ Physiol 2009;297(3):H983-996.

22. Ungvari ZI. Endothelium-derived bone morphogenic protein antagonists may counteract the proatherogenic vascular effects of bone morphogenetic protein 4. Circulation 2007;116(11):1221-1223.

23. Tait AR, Kyff JV, Crider B, Santibhavank V, Learned D, Finch JS. Changes in arterial oxygen saturation in cigarette smokers following general anaesthesia. Can J Anaesth 1990;37(4 Pt 1):423-428.

24. Najem B, Houssiere A, Pathak A, Janssen C, Lemogoum D, Xhaet O, Cuylits N, et al. Acute cardiovascular and sympathetic effects of nicotine replacement therapy. Hypertension 2006;47(6):1162-1167.

25. Birukov KG. Cyclic stretch, reactive oxygen species, and vascular remodeling. Antioxid Redox Signal 2009;11(7):1651-1667.

26. Lacolley P. Mechanical influence of cyclic stretch on vascular endothelial cells. Cardiovasc Res 2004;63(4):577-579.

27. Stanley AG, Patel H, Knight AL, Williams B. Mechanical strain-induced human vascular matrix synthesis: the role of angiotensin II. J Renin Angiotensin Aldosterone Syst 2000;1(1):32-35.

28. Kawaguchi H, Ozaki T, Murakami T, Iizuka K. Mechanical stress and human aortic smooth muscle cell proliferation. Exp Clin Cardiol 2001;6(1):24-28.

29. Kamath AR, Pai RG. Risk factors for progression of calcific aortic stenosis and potential therapeutic targets. Int J Angiol 2008;17(2):63-70.

30. Benetos A, Rudnichi A, Thomas F, Safar M, Guize L. Influence of heart rate on mortality in a French population: role of age, gender, and blood pressure. Hypertension 1999;33(1):44-52.

31. McEniery CM, Yasmin, McDonnell B, Munnery M, Wallace SM, Rowe CV, Cockerft JR, et al. Central pressure: variability and impact of cardiovascular risk factors: the Anglo-Cariff Collaborative Trial II. Hypertension 2008;51(6):1476-1482.

32. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360(9349):1903-1913.

33. Koylu E, Demirgoren S, London ED, Pogun S. Sex difference in up-regulation of nicotinic acetylcholine receptors in rat brain. Life Sci 1997;61(12):PL 185-190.